Your browser doesn't support javascript.
loading
Medical treatment of lung adenosquamous carcinoma / 中国综合临床
Clinical Medicine of China ; (12): 294-297, 2022.
Article de Zh | WPRIM | ID: wpr-956368
Bibliothèque responsable: WPRO
ABSTRACT
Adenosquamous carcinoma of the lung is a rare pathological type of non-small cell lung cancer. Adenosquamous carcinoma of the lung has a high degree of malignancy and poor clinical prognosis. Medical treatment plays an important role in patients who have lost the opportunity of operation or have recurrence and metastasis after operation. Platinum based chemotherapy is still the cornerstone of medical treatment. It is recommended that routine driver gene testing should be performed for patients with advanced lung adenosquamous carcinoma. For patients with sensitive driver genes, targeted therapy has a definite effect in some patients. Studies on markers related to immune checkpoint inhibitors suggest that patients with lung adenocarcinoma may benefit from immunotherapy, but there is still a lack of clinical practice data.
Mots clés
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Clinical Medicine of China Année: 2022 Type: Article
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Clinical Medicine of China Année: 2022 Type: Article